Volume 27, Number 10—October 2021
Research Letter
SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy
Aurélie Truffot, Julien Andréani, Marion Le Maréchal, Alban Caporossi, Olivier Epaulard, Raphaele Germi, Pascal Poignard, and Sylvie Larrat
Table
Clinical and biological characteristics of immunocompromised patient given bamlanivimab for COVID-19, France*
| Disease course, day† | Clinical manifestations | Treatment/action | Clinical samples‡ | RT-PCR results (mean Ct value) | VirSNIP Kit results | NGS clade |
|---|---|---|---|---|---|---|
| ‒20 |
First dose mRNA vaccine§ |
|||||
| ‒17 |
Venetoclax, rituximab |
|||||
| ‒4 |
Cough, fever, diarrhea, asthenia |
NA |
||||
| ‒3 |
NP |
Positive (27)¶ |
NA |
NA |
||
| 0 |
Bamlanivimab (700 mg) |
|||||
| 3 |
NP |
Positive (20) |
E484, N501Y |
20I/501Y.V1 |
||
| Blood |
Positive (37) |
NA |
NA |
|||
| Serum (30.7) |
||||||
| 6 |
Hospitalized at infectious diseases department |
NP |
Positive (21) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
|
| Blood |
Negative |
NA |
NA |
|||
| 7 |
Serum (23.2) |
|||||
| 10 |
Convalescent-phase plasma |
NP |
Positive (17) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
|
| 11 |
NP |
Positive (19) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
||
| Blood |
Positive (30) |
E484, N501Y |
20I/501Y.V1 ± 493R |
|||
| High-flow nasal oxygen |
Serum (26.5) |
|||||
| 13 |
Transferred to ICU |
|||||
| 15 |
NP |
Positive (21) |
E484Q, N501Y |
20I/501Y.V1+E484Q |
||
| 17 |
Blood |
Positive (31) |
E484, N501Y |
20I/501Y.V1 ± 493R ± 484K ± 484Q |
||
| Serum (22.9) |
||||||
| 21 |
High-dose corticotherapy protocol |
|||||
| 26 |
High-dose corticotherapy protocol |
|||||
| 33 |
Transferred to infectious disease department |
NP |
Positive (17) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
|
| Improvement in respiratory condition |
NA |
Blood |
Positive (37) |
NA |
NA |
|
| Serum (30.8) |
||||||
| 39 |
NP |
Positive (17) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
||
| Blood |
Negative |
|||||
| Serum (18.6) |
||||||
| 45 |
NP |
Positive (20) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
||
| 47 |
Treatment with remdesivir (10 d) |
|||||
| 52 |
NP |
Positive (31) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
||
| 54 |
NP |
Positive (30) |
E484Q, N501Y |
20I/501Y.V1 + E484Q |
||
| 56 |
Hospitalization for follow-up care |
|||||
| 61 |
NP |
Negative |
NA |
NA |
||
| 80 | NP | Negative | NA | NA |
*Blank cells indicate that clinical status was stable on that day, and no treatment was given. COVID-19, coronavirus disease; Ct, cycle threshold; D, day; ICU, intensive care unit; NA, not available; NP, nasopharyngeal swab specimen; NGS, next-generation sequencing; RT-PCR, reverse transcription PCR.
†Day 0 indicates first day of follow-up care at hospital.
‡Serologic results given by using the Wantai antibody test (index of positivity = 1).
§Vaccine BNT162b2 (Pfizer/BioNTech, https://www.pfizer.com).
¶Test was performed in an external laboratory (no sample was available for further analysis).
Page created: July 28, 2021
Page updated: September 19, 2021
Page reviewed: September 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.